1. COVID-19 public health emergency: general considerations for pre-IND meeting requests for COVID-19 related drugs and biological products : guidance for industry and investigators Publication: [Silver Spring, MD] : Center for Drug Evaluation and Research, May 2020 Subject(s): Biological ProductsCOVID-19 -- drug therapyDrug ApprovalDrug IndustryDrugs, InvestigationalDrug Evaluation, PreclinicalInvestigational New Drug ApplicationUnited StatesUnited States. Department of Health and Human Services.United States. Food and Drug Administration.
